Not investment advice. Educational platform. See Disclaimer.
NASDAQ: STOK
Stoke Therapeutics, Inc.
Healthcare | Biotechnology
No licensed closing price on file for STOK. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
EPS (TTM)$-3.34
Stoke Therapeutics, Inc. (NASDAQ: STOK) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:48 UTC.
Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
2026-03-27AuditorChanges in registrant's certifying accountantKPMGEstimatedSEC 8-K →
2026-03-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-10-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
Stoke Therapeutics, Inc. is a biotechnology company, listed on NASDAQ as STOK.
When did STOK last file with the SEC?
Stoke Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-30. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:48 UTC. This page is also available as JSON at /api/data?ticker=STOK and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for STOK and 5,000+ tickers.
Oxford Ledge
Search